NEW YORK, June 2, 2015 (GLOBE NEWSWIRE) -- The Rosen Law Firm, a global investor rights firm, reminds purchasers of Cellular Biomedicine Group Inc. (Nasdaq:CBMG) securities from June 18, 2014 through April 7, 2015 of the important June 22, 2015 lead plaintiff deadline in the class action lawsuit. The lawsuit seeks to recover damages for Cellular Biomedicine investors under the federal securities laws.
To join the Cellular Biomedicine class action, go to the firm's website at http://www.rosenlegal.com/cases-569.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The lawsuit alleges that the Company made false and/or misleading statements and/or failed to disclose that: (1) the Company used paid stock promoter to achieve its unsustainable $500m valuation, but failed to disclose such use in its regulatory filings; (2) the Company's "Car-T" technology experienced patient deaths and lacked any meaningful market value; and (3) as a result of the above, the Company's financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to join the class action and recover your losses, go to the firm's website at http://www.rosenlegal.com/cases-569.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.